Lilly Launches Its First Phase III Trial for Treatment of Alzheimer’s Disease

31 Mar

clipped from

Late-stage IDENTITY study of once-daily, oral agent is now enrolling

Eli Lilly and Company
(NYSE: LLY) has announced today the start of a Phase III clinical trial
studying LY450139, an investigational gamma secretase inhibitor for the
treatment of mild to moderate Alzheimer’s disease.

Slowing the rate of disease progression could preserve independent
functioning and quality of life for Alzheimer’s patients in the milder
stages of the disease, potentially delaying the onset of the severe stages
of the disease.

LY450139 is being tested
to see if it can slow the progression associated with Alzheimer’s disease
by inhibiting gamma-secretase, an enzyme that can create a sticky protein
called amyloid beta.

IDENTITY is a randomized, double-blind, placebo-controlled trial that
will be conducted in the U.S. and 21 additional countries.

information regarding the IDENTITY trial, including global
recruitment sites, may be found at

blog it


Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )


Connecting to %s

%d bloggers like this: